Blog Archives for tag interstitial lung disease

medicine

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

FESCA is very happy to share the news, that the U.S. Food and Drug Administration (FDA) has granted¬†¬† Fast Track… Continue reading »